NIACIN REVISITED - A RANDOMIZED, CONTROLLED TRIAL OF WAX-MATRIX SUSTAINED-RELEASE NIACIN IN HYPERCHOLESTEROLEMIA

被引:61
作者
KEENAN, JM [1 ]
FONTAINE, PL [1 ]
WENZ, JB [1 ]
MYERS, S [1 ]
HUANG, ZQ [1 ]
RIPSIN, CM [1 ]
机构
[1] UNIV MINNESOTA, DEPT FAMILY PRACTICE & COMMUNITY HLTH, MINNEAPOLIS, MN 55414 USA
关键词
D O I
10.1001/archinte.151.7.1424
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Two hundred one male and female subjects, aged 20 to 70 years, with elevated low-density lipoprotein cholesterol values (in the 75th to 95th percentiles), participated in a randomized, controlled, double-blind study using a new form of niacin (Enduracin), which employs a wax-matrix vehicle for sustained release. Four niacin treatment groups (daily doses of 2000, 1500, 1250, and 1000 mg) were compared with placebo- and diet-treated controls to determine side-effect profile and optimal range of efficacy. The groups given 2000 and 1500 mg demonstrated significant reductions in values of low-density lipoprotein cholesterol (26% and -19.3%, respectively), total cholesterol (-18.4% and -13.3%), and total cholesterol-high-density lipoprotein cholesterol ratio (-20.4% and -19.4%) when compared with diet- and placebo-treated controls. Smaller improvements were seen In high-density lipoprotein cholesterol and triglyceride levels. Blood chemistry monitoring indicated that reduction in low-density lipoprotein cholesterol level strongly correlated with an increase in baseline levels of some enzymes for niacin-treated subjects. The improved side-effect profile of the wax-matrix form of niacin was particularly notable. The dropout rate due to side effects was only 3.4% and was coupled with good medication compliance.
引用
收藏
页码:1424 / 1432
页数:9
相关论文
共 27 条
[1]   EFFECT OF A MODIFIED, WELL-TOLERATED NIACIN REGIMEN ON SERUM TOTAL CHOLESTEROL, HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND THE CHOLESTEROL TO HIGH-DENSITY LIPOPROTEIN RATIO [J].
ALDERMAN, JD ;
PASTERNAK, RC ;
SACKS, FM ;
SMITH, HS ;
MONRAD, ES ;
GROSSMAN, W .
AMERICAN JOURNAL OF CARDIOLOGY, 1989, 64 (12) :725-729
[2]   INFLUENCE OF NICOTINIC ACID ON SERUM CHOLESTEROL IN MAN [J].
ALTSCHUL, R ;
HOFFER, A ;
STEPHEN, JD .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1955, 54 (02) :558-559
[3]   CURRENT THERAPY FOR HYPERCHOLESTEROLEMIA [J].
BLUM, CB ;
LEVY, RI .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (24) :3582-3587
[4]   15 YEAR MORTALITY IN CORONARY DRUG PROJECT PATIENTS - LONG-TERM BENEFIT WITH NIACIN [J].
CANNER, PL ;
BERGE, KG ;
WENGER, NK ;
STAMLER, J ;
FRIEDMAN, L ;
PRINEAS, RJ ;
FRIEDEWALD, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 8 (06) :1245-1255
[5]  
DEMARKWAHNEFRIED W, 1990, J AM DIET ASSOC, V90, P223
[6]  
DOLECEK TA, 1986, J AM DIET ASSOC, V86, P752
[7]   COMPARISON OF EXCRETION OF NICOTINURIC ACID AFTER INGESTION OF 2 CONTROLLED RELEASE NICOTINIC-ACID PREPARATIONS IN MAN [J].
FIGGE, HL ;
FIGGE, J ;
SOUNEY, PF ;
SACKS, FM ;
SHARGEL, L ;
JANOSIK, JE ;
KAUL, AF .
JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 28 (12) :1136-1140
[8]   HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE [J].
FRICK, MH ;
ELO, O ;
HAAPA, K ;
HEINONEN, OP ;
HEINSALMI, P ;
HELO, P ;
HUTTUNEN, JK ;
KAITANIEMI, P ;
KOSKINEN, P ;
MANNINEN, V ;
MAENPAA, H ;
MALKONEN, M ;
MANTTARI, M ;
NOROLA, S ;
PASTERNACK, A ;
PIKKARAINEN, J ;
ROMO, M ;
SJOBLOM, T ;
NIKKILA, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) :1237-1245
[9]  
GRUNDY SM, 1981, J LIPID RES, V22, P24
[10]   RETEST RELIABILITY OF PLASMA-CHOLESTEROL AND TRIGLYCERIDE - THE LIPID RESEARCH CLINICS PREVALENCE STUDY [J].
JACOBS, DR ;
BARRETTCONNOR, E .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1982, 116 (06) :878-885